Alert share

Member Profile

MZM2511 Member Star
Total Cumulative Posts 52
Joined Jun 2021
Country MALAYSIA
Gender Male


Blogs

Blog TitleTotal PostsLast Published
RESEARCH FINDINGS ON THE COMPANIES814 Aug 2021

Comments

 User Comments
BlogBLOG: Kanger (0170), The Bamboo Flooring And Related Products Company Is Trying Hard To Secure Covid-19 Vaccines Business.
Blog 28 Jul 2021, 8:23:34 AM

Earlier this year, Sinopharm entered into a joint venture with UAE-based G42 to produce the Sinopharm Covid-19 vaccines in the country under the Hayat-Vax brand.

The made-in-UAE vaccine was the first Covid-19 vaccine to be produced in the Arab world.

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.

BlogBLOG: Kanger (0170) Has A Great Prospect To Secure Its Sinopharm Covid-19 Vaccine Distributorship In Malaysia
Blog 28 Jul 2021, 8:22:57 AM

The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.

Please refer to the full announcement as attached.

This announcement is dated 19 July 2021.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295

4.1 Quantity and specification of the Products
Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.
Specification: SARS COV-2 vaccine (Vero cell) inactivated, 6.5 U/0.5ml in prefilled syringe or vial (as per availability) and pack size either 2 doses per vial per box or Single dose per vial per box (as per availability). The Product is manufactured by Gulf Pharmaceutical Industries Julphar in the United Arab Emirates (HAYAT-VAX), i.e. G42 Medications Trading LLC (“Manufacturer”).

BlogBLOG: Kanger (0170), The Bamboo Flooring And Related Products Company Is Trying Hard To Secure Covid-19 Vaccines Business.
Blog 28 Jul 2021, 8:22:38 AM

The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.

Please refer to the full announcement as attached.

This announcement is dated 19 July 2021.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295

4.1 Quantity and specification of the Products
Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.
Specification: SARS COV-2 vaccine (Vero cell) inactivated, 6.5 U/0.5ml in prefilled syringe or vial (as per availability) and pack size either 2 doses per vial per box or Single dose per vial per box (as per availability). The Product is manufactured by Gulf Pharmaceutical Industries Julphar in the United Arab Emirates (HAYAT-VAX), i.e. G42 Medications Trading LLC (“Manufacturer”).

BlogBLOG: TracVirus and SafeTravelPass Services: A Lucrative Business of Nexgram from the Covid-19 Screening Test and Digital Facilitation Services for Inbound and Outbound Travelers
Blog 28 Jul 2021, 8:20:26 AM

Nexgram unit gets govt nod to operate SafeTravelPass Malaysia

KUALA LUMPUR (July 27): Nexgram Holdings Bhd’s 51%-owned subsidiary, Tri-G Technologies Sdn Bhd (Tri-G), has received an operation notification letter from the government for the implementation of the Covid-19 quarantine process using the TracAPM digital system.

In a stock exchange filing with Bursa Malaysia today, Nexgram said the TracAPM registration system, or better known as SafeTravelPass Malaysia, is the country’s official portal for Covid-19 entry registry and the booking of quarantine hotels.

“Tri-G is also authorised by Malaysia’s government for the handling of bookings and payments under business-to-business arrangements for all standard and premium private hotels nationwide,” the company said.

Source: https://www.theedgemarkets.com/article/nexgram-unit-gets-govt-nod-operate-safetravelpass-malaysia

BlogBLOG: TracVirus and SafeTravelPass Services: A Lucrative Business of Nexgram from the Covid-19 Screening Test and Digital Facilitation Services for Inbound and Outbound Travelers
Blog 28 Jul 2021, 8:19:42 AM

16 July 2021, Kuala Lumpur, Malaysia

Malaysia government system TracAPM Covid-19 entry-registration, or SafeTravelPass Malaysia, is official government entry-registry and quarantine hotels booking portal.

SafeTravelPass (STP QR Code) is officially recognised by the government upon arrival in Malaysia. Travellers can now conveniently access to SafeTravelPass Malaysia for Covid-19 Entry-registration, directly book and pay for Covid-19 quarantine hotels and services online at official rates, and skip multiple forms entries, duplicate processes, and miss match of hotel room frustrations upon arrival in KLIA.


 

CorporateSTOCK: NEXGRAM (0096)
Blog 21 Jul 2021, 1:21:02 PM

https://nexgram.co/2021/07/15/nexgrams-quarantine-management-system-for-inbound-travellers-officially-online-15-jul-2021-the-edge/

BlogBLOG: The Current Status of Selected Agreements Relating To NEXGRAM
Blog 06 Jul 2021, 7:03:49 PM

6.        A Memorandum of Understanding (MOU) between Nexgram Biomedic Sdn Bhd, a wholly owned subsidiary of Nexgram with Perbadanan Kemajuan Negeri Melaka, relating to the proposed sale and purchase of a piece of land in Melaka intended for development of Melaka Lifecare Specialist Project.

The progress of the MOU:

  1. Based on an announcement at BURSA dated  2 April 2021.
  • Indirect wholly owned subsidiary company, Nexgram Biomedic Sdn Bhd has on 1 April 2021, digitally signed an understanding with Perbadanan Kemajuan Negeri Melaka for the proposed sale and purchase of a piece of land situated in PT 8839 Mukim Bukit Baru, District of Melaka Tengah, State of Melaka measuring an area of approximately 24.78 acres.
  • The proposed acquisition of the Said Land is proposed to be developed as Melaka Lifecare Specialist Project with the proposed gross development value estimated at RM1.6 billion.
  • The proposed acquisition of the land will be dedicated for mix development comprising hospital building, service SOHO (annexed to the Hospital), Wellness Centre & Bioscience Research Centre, Retirement & Medical Tourism (annexed to the Wellness Centre), MM2H Program (annexed to the Wellness Centre), 3 Star Hotel & Condotel, and Commercial and Recreation Park.
  • The Proposed Sale and Purchase of the Said Land shall subject to the Parties entering a definitive agreement on the terms and conditions to be agreed mutually by the parties.
  • Full details of the Proposed Land Acquisition as well as the detail of the Melaka LifeCare Specialist Project as per Chapter 10 of the ACE Market Listing Requirements will be disclosed upon the signing of the definitive agreement.
  • Further announcement in relation to the Proposed Sale and Purchase will be made in due course, once the details of the terms and conditions have been finalised.

      2.   Based on an announcement at BURSA dated  6 July 2021.

  • Board of Directors of NEXGRAM is pleased to announce that NEXGRAM BIOMEDIC SDN BHD (“NBSB” OR “PURCHASER”) had on 1 July 2021 entered into a Sale and Purchase Agreement (“SPA”) with PERBADANAN KEMAJUAN NEGERI MELAKA (“PKNM” OR “VENDOR”) to acquire a piece of 99 years of leasehold land held under PT 8839, Mukim Bukit Baru, District of Melaka Tengah, State of Melaka with measuring an area of approximately 10.031 hectares (equivalent to 24.78 acres) (“the said Land”) with a purchase consideration of Ringgit Malaysia Sixty One Million Five Hundred Twenty Six Thousand Seven Hundred Fifty Seven and Sen Sixty (RM61,526,757.60) only (“the Purchase Price”) calculated at the rate of Ringgit Malaysia Fifty Seven (RM57.00) only per square foot (“Proposed Land Acquisition”).
  • The Proposed Land Acquisition shall be satisfied in cash by internal generated funds, financing and/or any future corporate exercise which will be announced in due course.

         Remark:

  1. The said SPA to acquire the land is subject to, the company: (i) appoint an Adviser, (ii) issue a circular which includes the information set out in Appendix 10B to its shareholders; and  (iii) seek shareholders’ approval of the transaction in a general meeting.
CorporateSTOCK: NEXGRAM (0096)
Blog 03 Jul 2021, 8:31:56 AM

Updates on Nexgram's 3QR 2021 results:

 

MY PERSONAL NOTES BASED ON THE 3QR 2021 REPORT:

1.      The approved capital reduction exercise was not yet been taken into account in the 3QR 2021. Probably will be done in 4QR 2021 accounts.

2.      No specific report on the progress of the revenue from Indonesian, RAFA Agreement on the medical gloves and gown.

 

NOTABLE NOTES FROM THE 3QR 2021 REPORT:

1.     Healthcare continues to progress well, with government project SafeTravelPass COVID-19 entry-registration, payment and management of Quarantine-Station and  government services contributing positively in current financial year.

My personal comment: 

It’s a POSITIVE NOTE, as the company recognized there is a contribution from TracAPM – SafeTravelPass in the current financial year. The system are in a business and generating revenue to Nexgram, instead of the Malaysia is currently closing her borders.

2.    COVID-19 tests partnership with government is looking at positive return in coming quarter after much capital investment in last two (2) quarters, in view of taking part of mass screening assignment engaged with government health facilities.

My personal comment: 

It’s a POSITIVE NOTE, as the company recognized that in the last two quarters, the cost from a big capital investment has pressured the profitability of the company quarters, but the company expected more positively on its profitability in incoming quarters, thanks to Nexgram’s involvement in the mass screening of Covid-19 assignment engaged with the government health facilities.

3.        Government project capital investment continue to weight on current quarter which is normal for concession early investment.

My personal comment: 

It’s a NEGATIVE  NOTE for short term, as the company recognized that the big capital investment done on the secured government project gave more cost to the company and affected the profitability in the last quarter.

4.        The Group other healthcare segment is expanding on capacity resulted in further cost. The healthcare segment had experienced lower margin and recent success in contracts shall expect to contribute to bottom line in coming quarter.

 My personal comment: 

It’s a NEGATIVE  NOTE, as the company recognized further cost will be occurred cause by further expanding in its healthcare business. In addition, will the added cost and the current lower margin of healthcare business will give more pressure on the company’s profitability in near future?

 

 

 

BlogBLOG: A Pre-3QR 2021 Reporting: A Glance at the Revenue and Profit Growth of Nexgram for 2QR 2021
Blog 03 Jul 2021, 8:29:26 AM

MY PERSONAL NOTES BASED ON THE 3QR 2021 REPORT:

1.      The approved capital reduction exercise was not yet been taken into account in the 3QR 2021. Probably will be done in 4QR 2021 accounts.

2.      No specific report on the progress of the revenue from Indonesian, RAFA Agreement on the medical gloves and gown.

 

NOTABLE NOTES FROM THE 3QR 2021 REPORT:

1.     Healthcare continues to progress well, with government project SafeTravelPass COVID-19 entry-registration, payment and management of Quarantine-Station and  government services contributing positively in current financial year.

My personal comment: 

It’s a POSITIVE NOTE, as the company recognized there is a contribution from TracAPM – SafeTravelPass in the current financial year. The system are in a business and generating revenue to Nexgram, instead of the Malaysia is currently closing her borders.

2.    COVID-19 tests partnership with government is looking at positive return in coming quarter after much capital investment in last two (2) quarters, in view of taking part of mass screening assignment engaged with government health facilities.

My personal comment: 

It’s a POSITIVE NOTE, as the company recognized that in the last two quarters, the cost from a big capital investment has pressured the profitability of the company quarters, but the company expected more positively on its profitability in incoming quarters, thanks to Nexgram’s involvement in the mass screening of Covid-19 assignment engaged with the government health facilities.

3.        Government project capital investment continue to weight on current quarter which is normal for concession early investment.

My personal comment: 

It’s a NEGATIVE  NOTE for short term, as the company recognized that the big capital investment done on the secured government project gave more cost to the company and affected the profitability in the last quarter.

4.        The Group other healthcare segment is expanding on capacity resulted in further cost. The healthcare segment had experienced lower margin and recent success in contracts shall expect to contribute to bottom line in coming quarter.

 My personal comment: 

It’s a NEGATIVE  NOTE, as the company recognized further cost will be occurred cause by further expanding in its healthcare business. In addition, will the added cost and the current lower margin of healthcare business will give more pressure on the company’s profitability in near future?

 

BlogBLOG: A Pre-3QR 2021 Reporting: A Glance at the Revenue and Profit Growth of Nexgram for 2QR 2021
Blog 03 Jul 2021, 8:28:34 AM

Updates on Nexgram's 3QR 2021 result:

SOME ANALYSIS ON THE 3QR 2021 RESULT OF NEXGRAM (0096)

Table: ANALYSIS ON THE 3QR 2021 RESULT OF NEXGRAM (0096)

Revenue and Net Profit / (Net Loss) For The Quarter

Quarter

1QR 2021

(RM)

2QR 2021

(RM)

3QR 2021

(RM)

Remarks

Revenue

12,945,612

33,293,774

 

27,716,795

 

3QR on 2QR, revenue decreased 16.8%  mainly due to The Group’s revenue decreased 16.8% due to the decrease in revenue  contribution from subsidiary in healthcare division ( may be referred to the decrease in contribution from the manufacturing of medical plastic products by its subsidiary, Arita Plastic.

Year on Year, 3QR revenue increased 515.6%  mainly due to revenue contribution from the new division (i.e. healthcare) which mainly attributable from manufacturing of medical plastic products, providing Tracvirus Covid-19 related services and distribution of Covid-19 test kits

Net Profit/(Net Loss)

(2,813,692)

1,405,641

(1,201,183)

3QR on 2QR, decreased ( incurred loss instead of profit in 2QR) mainly due to decrease in revenue  contribution from healthcare division which are manufacturing of medical plastic products. Also, the Group other healthcare segment is expanding on capacity resulted in further cost and the healthcare segment had experienced lower margin.

Year on Year, the net loss was stagnant at RM1.2 million.

Segmental Information For The Quarter

Segment   \  Quarter

1QR 2021

(RM)

2QR 2021

(RM)

3QR 2021

(RM)

Remarks

Medical  / Healthcare

Revenue

5,136,582

29,525,498

48,044,179

3QR on 2QR, revenue increased 62.7%

Profit/(Loss) Before Tax

(1,079,059)

55,828

(760,007)

3QR on 2QR, incurred loss from profit in 2QR.

The healthcare segment had experienced lower margin and decreased contribution from manufacturing of medical plastic.

ICT

Revenue

5,946,660

11,955,629

16,699,319

Qo3QR on 2QR,  revenue increased 39.7%.

Profit/(Loss) Before Tax

(449,232)

103,954

741,620

3QR on 2QR, profit increase 613%.

Logistics

Revenue

1,862,490

4,759,379

8,865,276

3QR on 2QR, revenue increased 86.2%.

Profit/(Loss) Before Tax

(345,605)

(826,319)

(812,173)

3QR on 2QR, loss slightly decreased.

Property Investment

Revenue

7,088

7,088

49,616

3QR on 2QR, revenue increased

Profit/(Loss) Before Tax

(832,188)

(811,776)

(1,305,618)

3QR on 2QR, loss increased

Assets And Liabilities Information

Quarter

1QR 2021

(RM)

2QR 2021

(RM)

3QR 2021

(RM)

Remarks

Fixed Deposit And Cash Balance

28,335,439

26,609,584

26,746,885

3QR on 2QR, the cash condition is slightly increased.

Total Current Assets

113,485,599

113,475,905

114,196,396

3QR on 2QR, the current assets per current liabilities ratio slightly decreased from 1.359 to 1.346.

Total Current Liabilities

83,861,078

83,498,791

84,849,590

Shareholder’s  Equity

108,879,189

120,486,796

121,482,625

Nexgram's shareholder equity on consolidated basis of its shares excluding treasury shares

 =  (RM121,482,625 ÷              

      2 15,119,923) x 100%

=    56.47  %   

 

Conclusion:

3QR on 2QR, shareholders equity  of its shares increased from 51.23%  in the last 2QR 2021 report to 56.47%

@@Remarks: GN3 risk ?? Lowered

Net Assets Per Share

0.0488

0.4504

4.511

3QR on 2QR, NTA slightly increased

 

BlogBLOG: Kanger (0170) Has A Great Prospect To Secure Its Sinopharm Covid-19 Vaccine Distributorship In Malaysia
Blog 27 Jun 2021, 8:12:07 AM

The Edge (26 June 2021):  

(MYEG) is ready to supply an initial 10 million doses of Covid-19 vaccines as soon as the Government opens up private market vaccinations, the group said after inking a letter of intent with Anhui Zhifei Biopharmaceutical Co Ltd (Zhifei) for the vaccines.

MYEG said the letter of intent was signed pursuant to its receipt of a letter of no objection from the government for the group to purchase Zhifei’s vaccine.

 

www.bursamalaysia.com (23 November 2020): 

"The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia."  

 

NOTE:

  1.  The Zhifei Longcom, China Covid-19 vaccine is still in their preliminary stage of approval process with WHO. I think only the vaccines with the WHO approval will be given approval by NPRA to be imported to Malaysia. Instead, the Sinopharm Covid-19 vaccine already approved by WHO.

      2.   Kanger’s proposal to purchase Covid-19 vaccines for private use in Malaysia already given the the letter of no objection from NIBM, an agency under MOSTI much                    earlier in November 2020.

BlogBLOG: Kanger (0170) Has A Great Prospect To Secure Its Sinopharm Covid-19 Vaccine Distributorship In Malaysia
Blog 25 Jun 2021, 8:33:43 AM

KUALA LUMPUR: Pharmaniaga Bhd (Pharmaniaga) has taken up a financing facility from Standard Chartered Malaysia Bhd for the import and distribution of Sinovac Covid-19 vaccines to the public and private sectors.

https://www.nst.com.my/business/2021/06/701495/pharmaniaga-takes-financing-facility-stanchart-import-distribution-covid-19

BlogBLOG: Kanger (0170) Has A Great Prospect To Secure Its Sinopharm Covid-19 Vaccine Distributorship In Malaysia
Blog 25 Jun 2021, 8:32:33 AM

He pointed out that it is expected that in August, some PRIVATE COMPANIES will be approved to introduce the new crown vaccine from China. For example, Sinopharm vaccine can also be registered in Malaysia by then.

Source: https://www.orientaldaily.com.my/news/nation/2021/06/24/420158
-----------------

"some PRIVATE COMPANIES " ??? (Its for a number of Covid-19 vaccines from China aimed to be distributed for private market. Pharmaniaga has been given the nod to import more Sinovac vaccine for private market).

Is this reffered to GLC only???

What is good for Kanger is, the company has already signed a collaboration agreement with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group)  for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia. Under the agreement, Sinopharm Group has appointed KIB as the DISTRIBUTOR  for the vaccines, medical devices and products in Malaysia. KIB will also undertake the marketing and promotion of Sinopharm Group's products in Malaysia.

BlogBLOG: TracVirus and SafeTravelPass Services: A Lucrative Business of Nexgram from the Covid-19 Screening Test and Digital Facilitation Services for Inbound and Outbound Travelers
Blog 22 Jun 2021, 8:55:41 AM

An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:

Report 1:  9 March 2021.

Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.

In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.

“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.

Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials

Source:  https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes

Report 2:  21 May2021.

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.     

Source:  https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/

Report 3:  27 May2021.                                                                                                                                                                                                                                                   “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.                                                          Source:   https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

 

MY FINDINGS:

  1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.
  2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.
  3. There will be a big probability that the report by Kanger official is true.  The company has started to register the said vaccine with NPRA.
CorporateSTOCK: NEXGRAM (0096)
Blog 19 Jun 2021, 8:25:06 AM

Increased in Profit of Nexgram for 2QR 2021

Analysis on Table 2 shows that the increased in revenues recorded in 2QR 2021 generated a chance for certain segments of businesses to record profitable results. For example, the medical/healthcare segment, ICT and logistics has recorded profit for each segment in 2QR 2021 compared to the losses recorded in the previous quarter report.

Barring any unforeseen circumstances, if there could be other probable increase in the revenue from each segment recorded, especially a probable great jump in the revenue from the medical/healthcare businesses, I cautiously feel that the profit for 3QR 2021 has a potential to increase.

 

CorporateSTOCK: NEXGRAM (0096)
Blog 19 Jun 2021, 8:24:28 AM

Increased in Revenue of Nexgram for 2QR 2021

Table 2 was prepared based on the 2QR 2021 results. The analysis shows that the increased in revenue recorded in 2QR 2021 was caused by:

  1. a substantial increase in revenue for the company’s medical/healthcare segment. QoQ, the revenues in this segment increased more than 400%, due to mainly attributable from manufacturing of medical plastic products, providing Tracvirus Covid-19 related services and distribution of Covid-19 test kits.
  2. an increased revenue (QoQ) recorded in other segments such as ICT and logistics.
  3. unchanged revenue in the property segment.

The new business activities related to healthcare/medical segment such as manufacturing of medical plastic products, providing Tracvirus Covid-19 related services and distribution of Covid-19 test kits contributed more than 70% increasing in the company’s total revenue in 2QR 2021.

Barring any unforeseen circumstances, I cautiously feel that the medical/healthcare business has potential to show more upside in its revenue in 3QR 2021, as the ongoing Covid-19 pandemic still needs more services related to it.  Furthermore, there could be other potential additional source of revenue can be generated by Nexgram from services earned from the total of people passing through our borders via its new healthcare business related to TracAPM – SafeTravelPass sevices. The TracAPM - SafeTravelPass services should probably increase the volume of medical/healthcare revenues from quarantine collection services.

CorporateSTOCK: NEXGRAM (0096)
Blog 19 Jun 2021, 8:23:44 AM

                                   TABLE 2: Analysis of the Financial Results for 2QR 2021

  REVENUE

1QR 2021

2QR 2021

                         REMARKS

RM12,945,612

RM33,293,774

QoQ revenue increased 157% due to mainly attributable from manufacturing of medical plastic products, providing Tracvirus Covid-19 related services and distribution of Covid-19 test kits.

YoY increased due to (same as above).

NET PROFIT/(LOSS) FOR THE PERIOD

1QR 2021

2QR 2021

                     REMARKS

(RM2,813,692)

RM1,405,641

 QoQ profit increased.

YoY – profit up (was mainly   attributed from the new division     (i.e. healthcare).

SEGMENTAL INFORMATION:   REVENUE AND PROFIT /LOSS FROM MEDICAL/HEALTHCARE

1QR 2021

2QR 2021

                        REMARKS

Revenue:

RM5,136,582

Revenue:

RM29,525,498

QoQ revenue increased 4 folds.

Profit/(loss)before tax:

(RM1,079,059)

Profit/(loss)before tax:

RM55,828

QoQ profit increase.

SEGMENTAL INFORMATION:   REVENUE AND PROFIT /LOSS FROM ICT

1QR 2021

2QR 2021

                       REMARKS

Revenue:

RM5,946,660

Revenue:

RM11,955,629

QoQ revenue increased.

Profit/(loss)before tax:

(RM449,232)

Profit/(loss)before tax:

RM103,954

QoQ profit increase.

SEGMENTAL INFORMATION:   REVENUE AND PROFIT /LOSS FROM LOGISTICS

1QR 2021

2QR 2021

                      REMARKS

Revenue:

RM1,862,490

Revenue:

RM4,759,379

QoQ revenue increased.

Profit/(loss)before tax:

(RM345,605)

Profit/(loss)before tax:

(RM826,319)

QoQ loss increased.

SEGMENTAL INFORMATION:   REVENUE AND PROFIT /LOSS FROM PROPERTY INVESTMENT

1QR 2021

2QR 2021

                      REMARKS

Revenue:

RM7,088

Revenue:

RM7,088

QoQ revenue stagnated.

Profit/(loss)before tax:

(RM832,188)

Profit/(loss)before tax:

(RM811,776)

QoQ loss decreased.

Sources: Quarterly reports namely 1QR 2021 and 2QR 2021.

CorporateSTOCK: NEXGRAM (0096)
Blog 19 Jun 2021, 8:23:01 AM

From the last quarter report, Nexgram (0096) showed us some improvement in their financial conditions. The 2QR 2021 showed that Nexgram has reported more than 100% increased in its revenue and was in the black again, after several quarters in the red.  The contribution of revenue from the company's new business namely healthcare division has increased. Other business segments namely the ICT and logistics also generated more revenue for the company. Based on the analysis on the revenue and profit growth recorded in 2QR 2021, I hope it can be useful for the reader to predict the company’s results in incoming 3QR 2021, which expected to be announced on the end of June 2021.

Let us see at Table 1 and Table 2 listed below:

TABLE 1: Financial Results for the Last Two Quarter Reports

Date

Financial Result (RM)

Announcement Date

Quarter

Revenue

Profit Before Tax

Net Profit

30 Dec 2020

31 Oct 2020

12,946,000

(2,838,000)

(2,814,000)

31 Mar 2021

31 Jan 2021

33,294,000

1,410,000

1,406,000

Sources: Quarterly reports namely the 1QR 2021 and 2QR 2021.

Based on Table 1, we can see that the revenue for 2QR 2021 (quarterly accounting period ended on 31 January 2021) has increased 157% from RM12.946 million in 1QR 2021 (quarterly accounting period ended on 31 October 2021) to RM33.294 million in 2QR 2021.

The 2QR 2021 report also showed that the company reported an increase in profitability by recorded a net profit amount of RM1.406 million in 2QR 2021 compared to a net loss of RM2.814 million reported in the 1QR 2021.

BlogBLOG: The Current Status of MOUs and Agreements Relating To KANGER (0170)
Blog 15 Jun 2021, 5:36:52 PM

As conclusion, rather than still progressing in its current business, which is bamboo flooring and related products, Kanger also in its plan to venture in other business activities.

1.   The company already involved in construction services.
2.    In a process to acquire Properties for business
3.    In a process to acquire  a company which involved in a construction material trading.
4.   And of course for Covid-19 vaccine business, they just in the process of trying to secure the said business. It's true to say that the most critical aspect to get is the approval        of Sinopharm vaccine in Malaysia by government/NPRA.

CorporateSTOCK: NEXGRAM (0096)
Blog 15 Jun 2021, 10:41:42 AM

1.  The new business activities related to healthcare/medical segment such as manufacturing of medical plastic products, providing Tracvirus Covid-19 related services and distribution of Covid-19 test kits contributed more than 70% increasing in the company’s total revenue in 2QR 2021. The incoming 3QR 2021 has a potential to show more upside in it revenue.

2.  If there could be other probable increase in the revenue from each segment recorded, especially a probable great jump in the revenue from the medical/healthcare businesses, I feel that the profit for 3QR 2021 has a potential to increase.

Overview Market Search portfolio More
Overview Market Search Portfolio More
Recently Viewed